Drug evaluation: STA-4783 - Enhancing taxane efficacy by induction of Hsp70

Current Opinion in Investigational Drugs

Volumn 7, Issue 6, 2006, Pages 574-580

  Gehrmann, Mathias ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; CARBOPLATIN; DOCETAXEL; DRUG METABOLITE; HEAT SHOCK PROTEIN 70; PACLITAXEL; STA 4783; STA 5313; STA 5370; STA 5393; STA 5512; UNCLASSIFIED DRUG; VINCRISTINE;

ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; CELL SURFACE; CLINICAL TRIAL; CYTOSKELETON; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SCREENING; DRUG SYNTHESIS; FATIGUE; HEADACHE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR CELL; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYDRAZINES; LUNG NEOPLASMS; MELANOMA; RNA, MESSENGER; TAXOIDS; TUBULIN MODULATORS;

EID: 33745134735     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. 18753 Studies with RP 56976 (taxotere): A semisynthetic analogue of Taxol Ringel I, Horwitz SB J NAT CANCER INST 1991 83 4 288-291
2. 484549 The current status of docetaxel in solid tumors. An MD Anderson Cancer Center review. Hong WK ONCOLOGY-NY 2002 16 6 Suppl 6 9-15
3. 509145 Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK J EXP MED 1997 186 8 1315-1322
4. 529521 American Association of Cancer Research 95th Annual Meeting - overnight report (part IV), Orlando, FL, USA Kibble A IDDB MEETING REPORT 2004 March 27-31
5. 531145 Synthesis and biological activities of STA-4783: A novel small molecule Taxol enhancer. Sun L, Chen S, Koya K, Xia Z, Tatsuta N, Korbut T, Du Z, Liang G, Zhou D, Ono M ACS MEETING 2004 227 Abs MEDI 111
6. 531401 STA-4783, a novel HSP70 inducer, enhances the anti-cancer activity of paclitaxel without increasing toxicity in preclinical studies. Koya K, Sun L, Chen S, Tatsuta N, Korbut T, Zhou D, Llang G, Wu Y, Du Z, Xia Z-Q, Dahl TA, Barsoum J, Ono M, Chen LB PROC AM ASSOC CANCER RES 2004 45 Abs 1504
7. 531791 A novel HSP-70 inducer STA-4783 enhances the anticancer activity of paclitaxel without altering paclitaxel pharmacokinetics. Preclinical pharmacokinetics, distribution and excretion study of STA-4783. Tatsuta N, Liang G, Wang Q, Press R, Zavorskas PA, Sayyarpour F, McKeon ME, Kitayama E, Zhou D, Dahl TA, Mendenhall S, Sun L, Xie Z, Ono M, Koya K PROC AM ASSOC CANCER RES 2004 45 Abs 2125
8. 531833 Pre-clinical toxicology evaluation of STA-4783 alone or combination with paclitaxel in rats, mice, and dogs. Zhou D, McKeon ME, Dahl TA, Kitayama E, Tastuta N, Sun L, Ono M, Li L, Barsoum J, Mendenhall S, Koya K PROC AM ASSOC CANCER RES 2004 46 Abs 2112
9. 532818 American Association for Cancer Research - 95th Annual Meeting (part X), Orlando, FL, USA Kar S IDDB MEETING REPORT 2004 March 27-31
10. 545546 STA-4783, a novel HSP inducer, enhances paclitaxel activity. Preclinical to clinical modeling Salgia R, Berkenblit A, Dezube B, Dahl TA, Koya K PROC AM SOC CLIN ONCOL 2004 23 Abs 3124
11. 572028 Synta raises $80 million. Synta Pharmaceuticals Corp PRESS RELEASE 2004 November 22
12. 601884 Synta Pharmaceuticals presents preliminary data at ASCO for STA-4783 in patients with non-small cell lung cancer and soft tissue sarcoma. Synta Pharmaceuticals Corp PRESS RELEASE 2005 May 17
13. 604045 STA-4783 in combination with paclitaxel induces heat shock protein 70 (hsp70) in a phase 1 trial. Berkenblit A, Supko J, Ryan DP, Seiden MV, Nagai M, Bertin J, Dahl T, Dezube B, Eder JP PROC AM SOC CLIN ONCOL 2005 24 Abs 2011
14. 604046 A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naive advanced non-small cell lung cancer (NSCLC). Jacobs M, Weber R, Hainsworth J, Schwartzberg L, Strauss J, Tatsuta N, Du Z, McLeod M, Dahl T, Salgia R PROC AM SOC CLIN ONCOL 2005 24 Abs 7106
15. 604047 Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcomas (STS). Sherman ML, Ryan C, Blackstein M, Mendelson D, Agarwala S, Dooley W, Dahl T, Demitri GD PROC AM SOC CLIN ONCOL 2005 24 Abs 9069
16. 614009 A phase I study of STA-4783, an inducer of heat shock protein 70, combined with paclitaxel in patients with advanced solid tumors. Berkenblit A, Supko JG, Eder JP, Proper J, Royer ES, Dahl TA, Dezube BJ CLIN CANCER RES 2003 9 16 Pt 2 6131S
17. 636051 A 2-stage, randomized, blinded phase 2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma Powderly J, Khan K, Urba W, Richards JM, Hurwitz C, McLeod M, Dahl TA, Sherman MS CLIN CANCER RES 2005 11 23 suppl Abs C95
18. 637030 Results of a phase 2 study of STA-4783 in combination with paclitaxel and carboplatin in patients with previously untreated advanced non-small cell lung cancer (NSCLC) Hainsworth J, Weber R, Jacobs M, Fehrenbacher L, Schwartzberg L, Kalman L, Mills G, Dooley W, McLeod M, Dahl TA, Sherman MS, Salgia R CLIN CANCER RES 2005 11 23 suppl Abs B112
19. 637039 Preliminary results of a phase 2 study of the novel heat shock protein 70 (hsp70) inducer STA-4783 in combination with paclitaxel in patients with soft tissue sarcomas. Baker LH, Ryan C, Agarwala S, Cranmer L, Blackstein M, D'Amato G, Mendelson D, Hurwitz C, McLeod M, Dahl T, Sherman MS, Demetri G CLIN CANCER RES 11 23 suppl Abs B108
20. 642694 Synta discontinues STA-5326 development for psoriasis. Synta Pharmaceuticals Corp PRESS RELEASE 2005 December 23
21. 652203 Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R J IMMUNOL 1997 158 9 4341-4350
22. 652205 Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. Gehrmann M, Pfister K, Hutzler P, Gastpar R, Margulis B, Multhoff G BIOL CHEM 2002 383 11 1715-1725
23. 668389 A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Multhoff G, Botzler C, Wesnet M, Muller E, Meier T, Wilmanns W, Issels RD INT J CANCER 1995 61 2 272-279
24. 668428 Product: STA-4783. Synta Pharmaceuticals Corp COMPANY WORLD WIDE WEB SITE 2006 May 19 http://www.syntapharma.com
25. 668520 Update on tubulin-binding agents. Attard G, Greystoke A, Kaye S, De Bono J PATHOL BIOL 2006 54 2 72-84
26. 669306 Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Multhoff G, Mizzen L, Winchester CC, Milner CM, Wenk S, Eissner G, Kampinga HH, Laumbacher B, Johnson J EXP HEMATOL 1999 27 11 1627-36
27. 669313 Mechanisms of Taxol resistance related to microtubules. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB ONCOGENE 2003 22 47 7280-95